Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

December 20, 2007

Primary Completion Date

June 14, 2010

Study Completion Date

June 14, 2010

Conditions
Psoriasis
Interventions
DRUG

ILV-094

SC and IV administration on days 1, 14, 28, and 42

Trial Locations (24)

6529

Parexel George, George

9301

FARMOVS Parexel (Pty) Ltd, Bloemfontein

10016

New York University Medical Center, New York

10029

Mount Sinai School of Medicine, New York

27710

Duke Clinical Reseach Unit, Durham

33143

Miami Research Associates, South Miami

MRA Clinical Research, South Miami

44195

The Cleveland Clinic Foundation, Cleveland

46256

Dawes Fretzin Clinical Research Group, Indianapolis

Dawes Fretzin Dermatology Group, Indianapolis

47714

Hudson Dermatology, Evansville

48059

Hamzavi Dermatology, Fort Gratiot

63117

Central Dermatology, St Louis

90212

David Stoll, MD, Beverly Hills

90404

Dermatology Research, Santa Monica

16635-0909

Altoona Center for Clinical Research, Duncansville

75246-1613

Baylor Research Institute, Dallas

T5K 1X3

Stratical Medical, Edmonton

T6G 2B7

University of Alberta, Hospital Site Clinical Sciences Building, Edmonton

T6G 2C8

The Northern Alberta Clinical Trials and Research Centre (NACTRC), Edmonton

M9L 3A2

Bio Pharma Services Inc, Toronto

N2J 1C4

K. Papp Clinical Research, Waterloo

H2K 4L5

Innovaderm Recherches Inc, Montreal

Unknown

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00563524 - Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis | Biotech Hunter | Biotech Hunter